Clinical trials: Allogeneic Stem-Cell Transplant
Multiple Myeloma, Refractory Multiple Myeloma
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Rationale: Giving bortezomib and low doses of chemotherapy and total-body irradiation before a donor stem cell transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00995059
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, bortezomib
- Sponsor
- Mayo Clinic
Breast Cancer, Iron Overload
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant.
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma
- Trial name
- NCT00602446
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Graft vs. Host Disease, Chronic Graft vs. Host Disease
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).
- Conditions
- Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
- Trial name
- NCT06824103
- Testing
- Ruxolitinib
- Where
- 22 sites in China
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Despite improvements in outcomes after Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), the risk of relapse remains high and is the most common cause of mortality after…
- Trial name
- UPCI 13-165 (NCT02204020)
- Testing
- 5-azacytidine (5-aza) maintenance therapy after transplant
- Where
- United States
- Sponsor
- University of Pittsburgh
Aplastic Anemia
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor.
- Trial name
- APARR (NCT06646497)
- Testing
- Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
- Where
- 26 sites in France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metachromatic Leukodystrophy
Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation
There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD.
- Trial name
- Azylis (NCT01303146)
- Testing
- rhARSA
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Combined Immune Deficiency (SCID)
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
Background: Severe combined immune deficiency (SCID) is a group of conditions where the immune system does not work properly. The only cure for most SCIDs is a stem cell transplant (getting cells from a donor).
- Trial name
- NCT04370795
- Testing
- Sirolimus, Busulfan, Horse -Anti-thymocyte
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematopoietic Stem Cell Transplant (HSCT)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.
- Trial name
- NCT06702111
- Where
- 2 sites in Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- The University of Hong Kong
Skin Microbiome, Graft Versus Host Disease
The Skin Microbiome in Graft Versus Host Disease
Based on the evidence on the impact of the intestinal microbiome on the Graft Versus Host Disease (GVHD) after allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT), it is hypothesized that the skin-microbiome may play a…
- Conditions
- Skin Microbiome, Graft Versus Host Disease, Graft Versus Host Disease in Skin
- Trial name
- NCT04231500
- Testing
- Skin swabs, Skin punch biopsies, additional blood sampling
- Where
- Switzerland
- Volunteers
- 74 people
- Sponsor
- University Hospital, Basel, Switzerland
Transplantation, Influenza Vaccines
Adjuvanted Influenza Vaccine in Stem Cell Transplant
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for transplant patients, studies have shown that…
- Trial name
- NCT02560909
- Testing
- FLUAD® influenza vaccine, FLUVIRAL®
- Volunteers
- 73 people
- Sponsor
- University Health Network, Toronto
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant.
- Conditions
- Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm
- Trial name
- NCT03807063
- Testing
- Rivogenlecleucel, Rimiducid
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic/Lymphoid Cancer
Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress
PURPOSE: As this is a randomized controlled trial, all subjects receiving stress management psychoeducation will be expected to obtain a new set of coping skills that will allow them to better deal with the stressors of…
- Trial name
- NCT02037568
- Testing
- fPER
- Where
- 2 sites in United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation
HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
Human cytomegalovirus (HCMV) infection is one of the most common and serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation, Graft vs Host Disease
- Trial name
- HSCT-HCMV01 (NCT07210242)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Chronic Graft Versus Host Disease (GVHD) is one of the most challenging complications in long term survivors of allogeneic stem cell transplantation.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03066466
- Testing
- Atorvastatin, Methotrexate, Tacrolimus
- Where
- United States
- Sponsor
- Loyola University
Leukemia, Acute Lymphoblastic Leukemia
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT00143559
- Testing
- Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- St. Jude Children's Research Hospital
Engraft Failure, Relapse
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
The investigators will conduct this prospective and randomized clinical trial, to evaluate the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with decitabine containing conditional regimen and NAC…
- Conditions
- Engraft Failure, Relapse, GVHD
- Trial name
- NCT04945096
- Testing
- decitabine, Acetylcysteine, Semustine
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Cell Transplantation
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT05501756
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multiple Myeloma
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality.
- Trial name
- AlloRelapseMM (NCT05675319)
- Testing
- Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD)
- Where
- 30 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Osteopetrosis
Stem Cell Transplantation for Children Affected With Osteopetrosis
Malignant infantile osteopetrosis (MIOP) is a rare fatal genetic disorder that is characterized by the bone's inability to regulate remodeling. The only curative therapy is hematopoietic stem cell transplantation.
- Trial name
- NCT00145587
- Testing
- Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Jude Children's Research Hospital
Immunocompromised Patients
Immunogenicity and Safety of Two Respiratory Syncytial Virus Vaccine Strategies in Lung and Allogeneic Haematopoietic Stem Cell Transplant Recipients.
Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections (ARIs), which occur in seasonal outbreaks. Among the adult population, immunocompromised individuals, particularly lung transplant recipients and…
- Trial name
- RSVAxID (NCT07863401)
- Testing
- RSVpreF3-AS01, RSVpreF3
- Where
- 16 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.